NEW YORK (GenomeWeb News) — Molecular diagnostics company GeneNews saw its fourth-quarter revenues rise sharply year over year after its colorectal cancer test was approved for marketing in New York, the company reported after the close of the market on Tuesday.

For the three months ended Dec. 31, 2012, the Toronto-based firm posted revenues of C$59,630 (US$58,658), up from C$2,840 a year ago. Revenues were derived completely from its ColonSentry gene expression assay for assessing a patient's risk for colorectal cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.